首页> 外文OA文献 >538P Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial

【2h】

538P Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial

机译：538P Vemurafenib在非黑色素瘤V600和非V600 BRAF突变癌症：ACSé篮子试验结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
P. Tomasini; J. Mazieres; C. Cropet; X.G. Troussard; D. Malka; I.L. Ray-Coquard; S. Leboulleux; A. Fléchon; B. Arnulf; M. Cancel; I. Bieche; S. Collot; S. Taieb; G. Garcia; A-M. Mandache; N. Colignon; M. Gavrel; M. Jimenez; N. Hoog-Labouret; J-Y. Blay;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial. [J] . J. Mazieres, L. Montané, F. Barlesi, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：oa12.05 vemurafenib患者患有V600和非V600 BRAF突变：来自Acsé试验的NSCLC队列的最终结果。
2. Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma [J] . Yibing Yan, Grant McArthur, Omid Hamid, Journal of Translational Medicine . 2014,第SUPPLEMENTa1期

机译：从BRIM7进行的活检和进行中活检的生物标志物分析-维拉非尼和Cobimetinib联合治疗BRAF V600突变的黑色素瘤的1B期试验
3. P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial [J] . Julien Mazieres, Claire Cropet, Fabrice Barlesi, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P3.02A-034 Vemurafenib患者患有BRAF突变的非小细胞肺癌（NSCLC）。 Acsé试验的初步结果
4. Development of Nanoliposomes for the Treatment of Braf V600e Mutated Parent and Vemurafenib-Resistant Melanoma [D] . Fu, Yige. 2021

机译：用于治疗BRAF V600E突变父母和vemureafenib抗性黑素瘤的纳米脂质体的研制
5. Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label Single-Arm Cohort of the Histology-Independent VE-BASKET Study [O] . Vivek Subbiah, Radj Gervais, Gregory Riely, -1

机译：vemureafenib对具有BRAF v600突变的非小细胞肺癌患者的疗效：开放标签单臂队列的组织学 - 独立的VE篮子研究
6. Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma [O] . Yibing Yan, Grant McArthur, Omid Hamid, 2014

机译：从BRIM7进行的活检和进行中活检的生物标记分析-维拉非尼和Cobimetinib联合治疗BRAF V600突变的黑色素瘤的1B期试验

538P Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial

著录项

引文网络

相似文献

相关主题

期刊订阅